Full-Time

Associate Director

T1D Strategy & Operations

Confirmed live in the last 24 hours

Vertex Pharmaceuticals

Vertex Pharmaceuticals

1,001-5,000 employees

Develops medicines for serious diseases

Compensation Overview

$139.6k - $209.3k/yr

+ Bonus + Equity Awards

Senior, Expert

Company Does Not Provide H1B Sponsorship

Boston, MA, USA

Hybrid-Eligible: work remotely up to two days per week; or work five days per week on-site with ad hoc flexibility.

Category
Project Management
Strategy Development
Business & Strategy
Required Skills
Excel/Numbers/Sheets
Connection
Connection
Connection
logo

Get referrals →

You have ways to get a Vertex Pharmaceuticals referral from your network.

💡

Applications through a referral are 3x more likely to get an interview!

Requirements
  • Outstanding communication of information and ideas (written, PowerPoint, verbal), to varied audiences including senior leadership and large team formats; can simplify the complex into a story
  • Analytical, able to glean insights from data using excel and communicate in a compelling, visual way
  • Strong collaboration skills, with an ability to influence multiple stakeholders; builds mutual trust, respect and cooperation among team members
  • Proven project management skills, including the ability to manage multiple complex tasks and competing priorities; can hold people accountable, and adapt to new projects rapidly to effectively drive results
  • Can think enterprise-wide, is highly curious, and has a strategic mindset
  • Self-motivated; acts independently and prioritizes appropriately; embraces unexpected changes or challenges and drives to improved solutions in a fast-paced environment
  • Proven ability to work in and influence a cross-functional team promoting collaboration and high performing team behaviors with an unwavering focus on what is best for the patients we serve
  • Consistently displays sound ethics, good judgment and demonstrates Vertex’s core values
  • Bachelor's degree
  • 8+ years of progressive, relevant experience (or an equivalent combination of experience & education) in strategic planning and program management; healthcare/biopharmaceuticals or consulting experience
Responsibilities
  • Partners with the US T1D VP & BU Leadership Team to proactively shape the launch plan, and autonomously manages launch activity tracking and launch readiness team
  • Drives the development of high-impact executive, cross-functional and cross-team presentations and communications, including executive presentations, business reviews, and department town halls
  • Manages the annual brand planning and budgeting process to ensure strategic alignment, avoid duplication, and drive milestone completion as well as the monthly budgeting process
  • In partnership with commercial operations, develops dashboards for launch KPIs, monitors ROI of key initiatives and identifies focus areas to drive action that accelerates our launch plan
  • Lead additional special BU strategic projects and high-profile initiatives, as appropriate
  • Develop agendas and manage key meetings to ensure that important decisions and action items are fully addressed, including BU Leadership and Launch Readiness meetings
  • Coordinate pull-through of HR, talent development, and team-culture related initiatives and activities including team onboarding activities and critical all team & regional meetings
  • Act as a liaison between cross functional colleagues to ensure alignment and coordination on a wide variety of cross-functional initiatives including annual kick off and plan of action meetings
  • Lead after action reviews of high impact projects; provide recommendations for simplification of processes and systems
Desired Qualifications
  • Launch experience strongly preferred
Vertex Pharmaceuticals

Vertex Pharmaceuticals

View

Vertex Pharmaceuticals develops medicines for serious diseases, focusing on conditions like cystic fibrosis. The company conducts extensive research and development to create new drugs, often collaborating with other biotech firms to enhance its therapeutic offerings. One of its notable products is ivacaftor, which has shown effectiveness in treating cystic fibrosis. Vertex differentiates itself from competitors through its commitment to scientific innovation and strategic partnerships that expand its research capabilities. The goal of Vertex Pharmaceuticals is to improve the quality of life for patients with severe and life-threatening conditions by bringing effective treatments to market.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Boston, Massachusetts

Founded

1989

Simplify Jobs

Simplify's Take

What believers are saying

  • Vertex's EU approval expands its cystic fibrosis treatment market.
  • Partnerships with Arbor and Orna enhance Vertex's gene therapy capabilities.
  • Increased focus on personalized medicine aligns with Vertex's patient-centric approach.

What critics are saying

  • Increased competition in cystic fibrosis could impact Vertex's market share.
  • Regulatory changes in the EU may delay Vertex's drug approvals.
  • High R&D costs and potential trial failures could strain Vertex's finances.

What makes Vertex Pharmaceuticals unique

  • Vertex focuses on transformative medicines for serious diseases, like cystic fibrosis.
  • The company invests heavily in R&D and strategic partnerships for drug development.
  • Vertex's innovative cell and gene therapies set it apart in the biotech industry.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Company News

Buniversity
May 1st, 2025
VERTEX upset Grayhound for spot at BLAST Showdown

VERTEX locked in a first-place finish at Fortress OCE Masters Fall 2022 Finals in Melbourne to qualify for BLAST Premier Fall Showdown.

BioSpace
Apr 14th, 2025
Vertex Researcher, Paul Negulescu Ph.D., Receives the 2025 Canada Gairdner International Award for Pioneering Research and Discovery of Medicines for Cystic Fibrosis

Vertex researcher, Paul Negulescu Ph.D., receives the 2025 Canada Gairdner International Award for pioneering Research and discovery of medicines for Cystic Fibrosis.

Biz Owner Daily
Apr 7th, 2025
EU Approves Expanded Label for Vertex Pharmaceuticals' Cystic Fibrosis Treatment

Vertex Pharmaceuticals has received approval from the European Union to broaden the label for its cystic fibrosis treatment.

Slater Sentinel
Mar 23rd, 2025
Stevens Capital Management LP Makes New $829,000 Investment in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Stevens Capital Management LP makes new $829,000 investment in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).

Investing.com
Mar 20th, 2025
BMO maintains Vertex stock Market Perform rating and $41 target

The reaffirmation of the rating and target came after Vertex held its first analyst day since its initial public offering in 2020.